NASDAQ:ARNAArena Pharmaceuticals Stock Price, Forecast & News

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARNA shares have increased by 69.7% and is now trading at $68.59. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arena Pharmaceuticals.

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Arena Pharmaceuticals.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($2.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.28) by $0.28. The biopharmaceutical company earned $0.26 million during the quarter, compared to analyst estimates of $1.58 million. Arena Pharmaceuticals had a negative return on equity of 29.30% and a negative net margin of 5,727.22%. The business's quarterly revenue was down 100.0% on a year-over-year basis. During the same period in the prior year, the business posted $12.10 EPS. View Arena Pharmaceuticals' earnings history.

Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

9 Wall Street analysts have issued 1 year price objectives for Arena Pharmaceuticals' stock. Their forecasts range from $56.00 to $95.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $72.38 in the next year. This suggests a possible upside of 5.5% from the stock's current price. View analysts' price targets for Arena Pharmaceuticals.

News headlines about ARNA stock have been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutArena Pharmaceuticals.

Some companies that are related to Arena Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Cytokinetics (CYTK), Canopy Growth (CGC), Inovio Pharmaceuticals (INO), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH) and Amarin (AMRN).

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Arena Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.14%), Wellington Management Group LLP (9.44%), State Street Corp (3.75%), Alliancebernstein L.P. (2.45%), Eagle Asset Management Inc. (1.88%) and Lord Abbett & CO. LLC (1.69%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Preston Klassen, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View institutional ownership trends for Arena Pharmaceuticals.

ARNA stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Perceptive Advisors LLC, APG Asset Management N.V., APG Asset Management N.V., Cormorant Asset Management LP, AXA, WINTON GROUP Ltd, and Morgan Stanley. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Randall E Woods, Robert Lisicki, Steven W Spector, and Vincent Aurentz. View insider buying and selling activity for Arena Pharmaceuticals.

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Bank of New York Mellon Corp, Asymmetry Capital Management L.P., Nuveen Asset Management LLC, Schroder Investment Management Group, BlackRock Inc., JPMorgan Chase & Co., and Invesco Ltd.. View insider buying and selling activity for Arena Pharmaceuticals.

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARNA stock can currently be purchased for approximately $68.59.

Arena Pharmaceuticals has a market capitalization of $3.45 billion and generates $806.43 million in revenue each year. The biopharmaceutical company earns $397.55 million in net income (profit) each year or $7.69 on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.

The official website for Arena Pharmaceuticals is www.arenapharm.com.

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]